BeStock  
Stocks › Biotechnology › LTGO

Latigo Biotherapeutics LTGO

US equityMarket cap rank #3223Biotechnology
$15.52 −$0.74 (-4.55%)
Market closed · Oct 8, 7:00 am ET · Last extended-hours $15.89 +2.38%
Open$16.22
Prev close$16.26
Day range$15.27 – $16.35
Volume241.5K
Market cap$1.03B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$0.00
Operating profit-$25.81M-0.2% YoY
Net profit-$25.80M+0.1% YoY
Diluted EPS-$0.43+26.9% YoY
Free cash flow-$21.39M+0.9% YoY
Operating cash flow-$21.28M

Revenue, last 4 quarters

$0.0Mar '25$0.0Jun '25$0.0Mar '26$0.0Jun '26

Net profit, last 4 quarters

$-21.0MMar '25$-25.8MJun '25$-23.0MMar '26$-25.8MJun '26

Diluted EPS by quarter

-0.48Mar '25-0.59Jun '25-0.52Mar '26-0.43Jun '26

Free cash flow by quarter

$-21.3MMar '25$-21.6MJun '25$-27.1MMar '26$-21.4MJun '26

Profitability & balance sheet

Return on assets-171.6%
Current ratio1.15
Liabilities / assets526.3%
Cash & investments$55.00M
Total debt$30.55M
Net cash (debt)$24.46M

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q2 2025 Q1
Research & Development $21.23M $17.63M $99.53M $22.92M $18.69M
Selling and Admin Expenses $4.58M $5.80M $10.86M $2.82M $2.82M
Non-Operating Interest Income $264,000.00 $474,000.00 $2.94M $868,000.00 $517,000.00
Non-Operating Interest Expense $251,000.00 – – $0.00 –
Other Income (Expense) -$2,000.00 $1,000.00 -$1.72M -$958,000.00 $43,000.00
Other Non-Operating Income (Expenses) -$2,000.00 $1,000.00 -$1.72M -$958,000.00 $43,000.00
Pretax Profit -$25.80M -$22.96M -$109.17M -$25.84M -$20.95M
Net Profit -$25.80M -$22.96M -$109.17M -$25.84M -$20.95M
Profit from Continuing Operations -$25.80M -$22.96M -$109.17M -$25.84M -$20.95M
Net Income to Parent Company -$25.80M -$22.96M -$109.17M -$25.84M -$20.95M
Net Income to Common Stockholders -$25.80M -$22.96M -$109.17M -$25.84M -$20.95M
Basic EPS -$0.43 -$0.52 -$2.48 -$0.59 -$0.48
Operating Profit -$25.81M -$23.44M -$110.39M -$25.75M -$21.51M
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $25.81M $23.44M $110.39M $25.75M $21.51M
-General & Admin Expense $4.58M $5.80M $10.86M $2.82M $2.82M
Diluted EPS -$0.43 -$0.52 -$2.48 -$0.59 -$0.48
Net Non-Operating Interest Income (Expense) $13,000.00 $474,000.00 $2.94M $868,000.00 $517,000.00

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2024 ANNUAL
Total Liabilities $340.84M $303.16M $307.19M $152.46M
Total Current Liabilities $51.58M $14.49M $18.45M $14.44M
Payables $3.57M $4.46M $5.02M $7.07M
-Accounts Payable $3.57M $4.46M $5.02M $7.07M
Current Accrued Expenses $8.78M $8.63M $8.67M $4.71M
Short-Term Debt and Capital Lease Obligation $30.60M $502,000.00 $563,000.00 $387,000.00
-Current Debt $29.90M – – –
-Current Capital Lease Obligation $705,000.00 $502,000.00 $563,000.00 $387,000.00
Other Current Liabilities $5.15M – – $250,000.00
Total Non-Current Liabilities $289.27M $288.67M $288.74M $138.03M
Other Non-Current Assets $3.80M $2.84M $616,000.00 $290,000.00
Total Assets $64.76M $50.58M $75.52M $22.86M
Total Current Assets $59.20M $46.84M $73.83M $21.16M
Cash and Cash Equivalents & Short-Term Investments $55.00M $42.18M $69.44M $17.92M
-Cash and Cash Equivalents $55.00M $42.18M $69.44M $17.92M
Prepaid Assets $4.00M $4.47M $4.20M $3.25M
Restricted Cash $194,000.00 $192,000.00 $192,000.00 $0.00
Total Non-Current Assets $5.56M $3.74M $1.69M $1.70M
Net PPE $1.76M $900,000.00 $1.07M $1.41M
-Gross PPE $2.71M $1.80M $1.93M $2.02M
Long Term Debt and Capital Lease Obligation $648,000.00 $52,000.00 $127,000.00 $464,000.00
-Long Term Capital Lease Obligation $648,000.00 $52,000.00 $127,000.00 $464,000.00
Retained Earnings -$291.89M -$266.09M -$243.13M -$133.96M
Convertible preferred securities $288.58M $288.58M $288.58M $137.53M
Other Non-Current Liabilities $35,000.00 $35,000.00 $35,000.00 $35,000.00
Total Equity -$276.08M -$252.58M -$231.67M -$129.60M
Stockholders' Equity -$276.08M -$252.58M -$231.67M -$129.60M
Capital Stock $0.00 $0.00 $0.00 $0.00
-Common Stock $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $15.81M $13.51M $11.46M $4.37M
-Accumulated Depreciation -$953,000.00 -$901,000.00 -$854,000.00 -$605,000.00

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q2 2025 Q1
Financing Cash Flow $34.18M -$230,000.00 $149.50M -$1,000.00 $99.43M
Net PPE Purchase and Sale -$110,000.00 $0.00 -$136,000.00 -$33,000.00 -$102,000.00
Net Cash Flow from Continuing Investing Activities -$110,000.00 $0.00 -$136,000.00 -$33,000.00 -$102,000.00
Net Other Financing Charges -$974,000.00 -$308,000.00 – – –
-Change in Other Current Liabilities -$160,000.00 -$136,000.00 -$446,000.00 -$94,000.00 -$94,000.00
-Change in Other Current Assets -$1.00M -$2.26M -$234,000.00 $120,000.00 $146,000.00
-Change in Payables and Accrued Expense $2.58M -$3.59M $4.18M $2.53M -$726,000.00
-Change in Prepaid Assets $472,000.00 -$274,000.00 -$979,000.00 -$1.05M -$1.11M
Change in Working Capital $1.89M -$6.26M $2.52M $1.51M -$1.78M
Net Cash Flow from Continuing Financing Activities $34.18M -$230,000.00 $149.50M -$1,000.00 $99.43M
Net Preferred Stock Issuance $0.00 $0.00 $149.38M -$1,000.00 $99.43M
Net cash flow from investing -$110,000.00 $0.00 -$136,000.00 -$33,000.00 -$102,000.00
Free Cash Flow -$21.39M -$27.07M -$97.69M -$21.59M -$21.26M
Beginning Cash Balance $42.42M $69.72M $17.92M $96.09M $17.92M
Net Change in Cash $12.79M -$27.30M $51.80M -$21.59M $78.18M
Ending Cash Balance $55.21M $42.42M $69.72M $74.50M $96.09M
Proceeds from Stock Option Exercised $153,000.00 $78,000.00 $117,000.00 $0.00 $0.00
Other Non-Cash Items $432,000.00 $124,000.00 $444,000.00 $97,000.00 $85,000.00
Depreciation & Depletion & Amortization $52,000.00 $47,000.00 $249,000.00 $66,000.00 $67,000.00
Net Income from Continuing Operations -$25.80M -$22.96M -$109.17M -$25.84M -$20.95M
Net cash flow from continuing operations -$21.28M -$27.07M -$97.56M -$21.56M -$21.16M
Operating Cash Flow -$21.28M -$27.07M -$97.56M -$21.56M -$21.16M
Net Common Stock Issuance – – $0.00 – –

Discussion

No comments yet — be the first to weigh in on LTGO.

Leave a comment

Scroll to Top